<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02467842</url>
  </required_header>
  <id_info>
    <org_study_id>NBP607-QIV_FluA_III_2014</org_study_id>
    <nct_id>NCT02467842</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Quadrivalent Influenza Vaccine (NBP607-QIV) in Adults and Elderly Subjects</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess the Immunogenicity and Safety of Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine in Adults and Elderly Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SK Chemicals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>SK Chemicals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      All participants received a single dose of their assigned vaccine on Day 0. They were
      followed up for immunogenicity and safety through Day 21 post-vaccination. Serious adverse
      events were collected for 6 months post-vaccination.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a randomized controlled phase III trial undertaken in 10 university hospitals of South
      Korea, adults and elderly subjects were randomly assigned in a 2:1:1 ratio to NBP607-QIV
      versus cell culture-based trivalent inactivated influenza vaccine (TIV), NBP607-Y and
      NBP607-V. Immunogenicity was assessed 3 weeks after vaccination by hemagglutination
      inhibition (HI) assay. Safety was assessed for 6 months post-vaccination: solicited adverse
      events for 7 days, unsolicited adverse events (AEs) for 21 days and serious adverse events
      (SAE) for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric Mean HI Titers (GMTs) After Vaccination in All Subjects</measure>
    <time_frame>At Day 21 post vaccination.</time_frame>
    <description>GMTs of anti-influenza antibodies were measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. For each A strain, the titers were made with the pooled TIV group (NBP60-Y and NBP607-V).
For each A strain, the comparion was made with the pooled TIV groups (Y+V/QIV). For each B strain, the comparison was made with the corresponding TIV group(i.e. for B/Yamagata, Geometric Mean Titer Ratio (GMR) is Y/QIV).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion Rate (SCR) After Vaccination in All Subjects</measure>
    <time_frame>At Day 21 post vaccination.</time_frame>
    <description>SCR was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroconversion was defined as the proportion of subjects who met either (1) post-vaccination HI titer of ≥ 1:40 for subjects with pre-vaccination HI titer of &lt;1:10 or (2) Four-fold increase in post-vaccination HI titer for subjects with pre-vaccination HI titer of ≥ 1:10
For each A strain, the comparion was made with the pooled TIV groups (Y+V minus QIV). For each B strain, the comparison was made with the corresponding TIV group(i.e. for B/Yamagata, Difference of SCR (Diff.SCR) is Y minus QIV).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection Rate (SPR) of NBP607-QIV in the Elderly Subject Aged ≥60 Years</measure>
    <time_frame>At Day 21 post vaccination.</time_frame>
    <description>SPR of NBP607-QIV was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroprotection was defined as the proportion of subjects whose post-vaccination HI titer increased to ≥1:40.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroconversion Rate (SCR) of NBP607-QIV in the Elderly Subject Aged ≥60 Years</measure>
    <time_frame>At Day 21 post vaccination.</time_frame>
    <description>SCR was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroconversion was defined as the proportion of subjects who met either (1) post-vaccination HI titer of ≥ 1:40 for subjects with pre-vaccination HI titer of &lt;1:10 or (2) Four-fold increase in post-vaccination HI titer for subjects with pre-vaccination HI titer of ≥ 1:10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Ratio (GMR) of NBP607-QIV in the Elderly Subject Aged ≥60 Years</measure>
    <time_frame>At Day 21 post vaccination.</time_frame>
    <description>GMR was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. GMR was defined as the fold-rise of the geometric mean HI titer from pre- to post-vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean HI Titers (GMTs) of Each B Strain After Vaccination in All Subjects</measure>
    <time_frame>At Day 21 post vaccination.</time_frame>
    <description>GMTs of anti-influenza antibodies were measured for B strains: B/Victoria, and B/Yamagata.
For each B strain, the comparison was made with the TIV group which did not contain the correponding B strain (i.e. for B/Yamagata, Geometric Mean Titer Ratio (GMR) is V/QIV).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Rate (SCR) of B Strain After Vaccination in All Subjects</measure>
    <time_frame>At Day 21 post vaccination.</time_frame>
    <description>SCR was measured for each B strain: B/Victoria, and B/Yamagata. Seroconversion was defined as the proportion of subjects who met either (1) post-vaccination HI titer of ≥ 1:40 for subjects with pre-vaccination HI titer of &lt;1:10 or (2) Four-fold increase in post-vaccination HI titer for subjects with pre-vaccination HI titer of ≥ 1:10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroprotection Rate (SPR) of NBP607-QIV in the Adults Aged 19 to 59 Years</measure>
    <time_frame>At Day 21 post vaccination.</time_frame>
    <description>SPR of NBP607-QIV was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroprotection was defined as the proportion of subjects whose post-vaccination HI titer increased to ≥1:40.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seroconversion Rate (SCR) of NBP607-QIV in the Adults Aged 19 to 59 Years</measure>
    <time_frame>At Day 21 post vaccination.</time_frame>
    <description>SCR was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroconversion was defined as the proportion of subjects who met either (1) post-vaccination HI titer of ≥ 1:40 for subjects with pre-vaccination HI titer of &lt;1:10 or (2) Four-fold increase in post-vaccination HI titer for subjects with pre-vaccination HI titer of ≥ 1:10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Ratio (GMR) of NBP607-QIV in the Subjects Aged 19 to 59 Years</measure>
    <time_frame>At Day 21 post vaccination.</time_frame>
    <description>GMR was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. GMR was defined as the fold-rise of the geometric mean HI titer from pre- to post-vaccination</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1503</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>NBP607-QIV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants aged 19 years and older received a 0.5mL single intramuscular dose of Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NBP607-Y</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants aged 19 years and older received a 0.5mL single intramuscular dose of Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata on Day 0</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NBP607-V</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants aged 19 years and older received a 0.5mL single intramuscular dose of Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria on Day 0</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NBP607-QIV</intervention_name>
    <description>Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria</description>
    <arm_group_label>NBP607-QIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NBP607-Y</intervention_name>
    <description>Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata</description>
    <arm_group_label>NBP607-Y</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NBP607-V</intervention_name>
    <description>Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria</description>
    <arm_group_label>NBP607-V</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults aged 19 years and older

          -  Those who are able to comply with the requirements for the study

          -  If women, a negative pregnancy test and willingness to use birth control measures for
             the entire study duration

        Exclusion Criteria:

          -  Disorders in immune function

          -  Any malignancy or lymphoproliferative disorder

          -  History of Guillain-Barré syndrome

          -  Individuals with a known bleeding diathesis, or any condition that may be associated
             with a prolonged bleeding time

          -  Experience of fever (&gt;38.0 ℃) within 24 hours following vaccination

          -  Body temperature &gt;38.0 ℃ at the vaccination day

          -  Concomitant medications/therapy such as immunosuppressants or immune modifying drugs,
             systemic corticosteroids, immunoglobulins, blood or blood- derived products within 3
             months

          -  Influenza vaccination within 6 months

          -  Subjects who have participated in other interventional study within 4 weeks

          -  Any vaccination within 1 month

          -  Those who are planning to receive any vaccine within 1 month from the study vaccine

          -  Individuals with any serious chronic or progressive disease

          -  Pregnant or breast-feeding women

          -  Any other reason that in the opinion of the investigator might interfere with the
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Woo Joo Kim, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Won Suk Choi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seong-Heon Wie, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University St. Vincent's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jin Soo Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacob Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Kangnam Sacred Heart Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shin Woo Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hye Won Jeong, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungbuk University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sook-In Jung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonnam University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yeon-Sook Kim, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chungnam University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Heung Jeong Woo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hallym University Dongtan Sacred Heart Hospital</affiliation>
  </overall_official>
  <results_reference>
    <citation>Choi WS, Noh JY, Song JY, Cheong HJ, Wie SH, Lee JS, Lee J, Kim SW, Jeong HW, Jung SI, Kim YS, Woo HJ, Kim KH, Kim H, Kim WJ. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects. Hum Vaccin Immunother. 2017 Jul 3;13(7):1653-1660. doi: 10.1080/21645515.2017.1297351. Epub 2017 Apr 13.</citation>
    <PMID>28406746</PMID>
  </results_reference>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>June 3, 2015</study_first_submitted>
  <study_first_submitted_qc>June 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <results_first_submitted>December 6, 2018</results_first_submitted>
  <results_first_submitted_qc>April 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 8, 2020</results_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza vaccine</keyword>
  <keyword>Quadrivalent</keyword>
  <keyword>Inactivated cell culture-derived</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NBP607-QIV</title>
          <description>Participants received a 0.5mL single intramuscular dose on Day 0
NBP607-QIV: Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria</description>
        </group>
        <group group_id="P2">
          <title>NBP607-Y</title>
          <description>Participants received a 0.5mL single intramuscular dose on Day 0
NBP607-Y: Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata</description>
        </group>
        <group group_id="P3">
          <title>NBP607-V</title>
          <description>Participants received a 0.5mL single intramuscular dose on Day 0
NBP607-V: Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="752"/>
                <participants group_id="P2" count="373"/>
                <participants group_id="P3" count="378"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="752"/>
                <participants group_id="P2" count="373"/>
                <participants group_id="P3" count="378"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NBP607-QIV</title>
          <description>Participants aged 19 years and older received a 0.5mL single intramuscular dose on Day 0
NBP607-QIV: Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria</description>
        </group>
        <group group_id="B2">
          <title>NBP607-Y</title>
          <description>Participants aged 19 years and older received a 0.5mL single intramuscular dose on Day 0
NBP607-Y: Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata</description>
        </group>
        <group group_id="B3">
          <title>NBP607-V</title>
          <description>Participants aged 19 years and older received a 0.5mL single intramuscular dose on Day 0
NBP607-V: Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="752"/>
            <count group_id="B2" value="373"/>
            <count group_id="B3" value="378"/>
            <count group_id="B4" value="1503"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>19 to 59 years old</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="599"/>
                    <measurement group_id="B2" value="299"/>
                    <measurement group_id="B3" value="305"/>
                    <measurement group_id="B4" value="1203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60 years old and older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="73"/>
                    <measurement group_id="B4" value="300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="476"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="233"/>
                    <measurement group_id="B4" value="947"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="276"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="145"/>
                    <measurement group_id="B4" value="556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean HI Titers (GMTs) After Vaccination in All Subjects</title>
        <description>GMTs of anti-influenza antibodies were measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. For each A strain, the titers were made with the pooled TIV group (NBP60-Y and NBP607-V).
For each A strain, the comparion was made with the pooled TIV groups (Y+V/QIV). For each B strain, the comparison was made with the corresponding TIV group(i.e. for B/Yamagata, Geometric Mean Titer Ratio (GMR) is Y/QIV).</description>
        <time_frame>At Day 21 post vaccination.</time_frame>
        <population>Per Protocol Set.</population>
        <group_list>
          <group group_id="O1">
            <title>NBP607-QIV</title>
            <description>Participants aged 19 years and older received a 0.5mL single intramuscular dose on Day 0
NBP607-QIV: Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria</description>
          </group>
          <group group_id="O2">
            <title>NBP607-Y</title>
            <description>Participants aged 19 years and older received a 0.5mL single intramuscular dose on Day 0
NBP607-Y: Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata</description>
          </group>
          <group group_id="O3">
            <title>NBP607-V</title>
            <description>Participants aged 19 years and older received a 0.5mL single intramuscular dose on Day 0
NBP607-V: Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean HI Titers (GMTs) After Vaccination in All Subjects</title>
          <description>GMTs of anti-influenza antibodies were measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. For each A strain, the titers were made with the pooled TIV group (NBP60-Y and NBP607-V).
For each A strain, the comparion was made with the pooled TIV groups (Y+V/QIV). For each B strain, the comparison was made with the corresponding TIV group(i.e. for B/Yamagata, Geometric Mean Titer Ratio (GMR) is Y/QIV).</description>
          <population>Per Protocol Set.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="748"/>
                <count group_id="O2" value="371"/>
                <count group_id="O3" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="329.76" lower_limit="309.17" upper_limit="351.71"/>
                    <measurement group_id="O2" value="334.98" lower_limit="313.91" upper_limit="357.47"/>
                    <measurement group_id="O3" value="334.98" lower_limit="313.91" upper_limit="357.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="401.21" lower_limit="378.87" upper_limit="424.87"/>
                    <measurement group_id="O2" value="377.34" lower_limit="356.47" upper_limit="399.44"/>
                    <measurement group_id="O3" value="377.34" lower_limit="356.47" upper_limit="399.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.74" lower_limit="156.11" upper_limit="171.73"/>
                    <measurement group_id="O2" value="144.65" lower_limit="135.54" upper_limit="154.37"/>
                    <measurement group_id="O3" value="123.08" lower_limit="115.39" upper_limit="131.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.82" lower_limit="119.16" upper_limit="130.75"/>
                    <measurement group_id="O2" value="93.29" lower_limit="87.43" upper_limit="99.53"/>
                    <measurement group_id="O3" value="112.20" lower_limit="105.20" upper_limit="119.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMR of A/H1N1 strain (GMTs of pooled TIV/QIV)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of GMTs was concluded if the upper limit of 95% confidence interval of the GMR (active comparator/experimental) was ≤1.5 for each strain.</non_inferiority_desc>
            <param_type>GMR (pooled TIV/QIV)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.94</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMR of A/H3N2 strain (GMTs of pooled TIV/QIV)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of GMTs was concluded if the upper limit of 95% confidence interval of the GMR (active comparator/experimental) was ≤1.5 for each strain.</non_inferiority_desc>
            <param_type>GMR (pooled TIV/QIV)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.87</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMR of B/Yamagata strain (GMTs of TIV/QIV)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of GMTs was concluded if the upper limit of 95% confidence interval of the GMR (active comparator/experimental) was ≤1.5 for each strain.</non_inferiority_desc>
            <param_type>GMR (TIV/QIV)</param_type>
            <param_value>0.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>0.95</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMR of A/H1N1 strain (GMTs of TIV/QIV)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of GMTs was concluded if the upper limit of 95% confidence interval of the GMR (active comparator/experimental) was ≤1.5 for each strain.</non_inferiority_desc>
            <param_type>GMR (TIV/QIV)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Rate (SCR) After Vaccination in All Subjects</title>
        <description>SCR was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroconversion was defined as the proportion of subjects who met either (1) post-vaccination HI titer of ≥ 1:40 for subjects with pre-vaccination HI titer of &lt;1:10 or (2) Four-fold increase in post-vaccination HI titer for subjects with pre-vaccination HI titer of ≥ 1:10
For each A strain, the comparion was made with the pooled TIV groups (Y+V minus QIV). For each B strain, the comparison was made with the corresponding TIV group(i.e. for B/Yamagata, Difference of SCR (Diff.SCR) is Y minus QIV).</description>
        <time_frame>At Day 21 post vaccination.</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>NBP607-QIV</title>
            <description>Participants aged 19 years and older received a 0.5mL single intramuscular dose on Day 0
NBP607-QIV: Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria</description>
          </group>
          <group group_id="O2">
            <title>NBP607-Y</title>
            <description>Participants aged 19 years and older received a 0.5mL single intramuscular dose on Day 0
NBP607-Y: Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata</description>
          </group>
          <group group_id="O3">
            <title>NBP607-V</title>
            <description>Participants aged 19 years and older received a 0.5mL single intramuscular dose on Day 0
NBP607-V: Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate (SCR) After Vaccination in All Subjects</title>
          <description>SCR was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroconversion was defined as the proportion of subjects who met either (1) post-vaccination HI titer of ≥ 1:40 for subjects with pre-vaccination HI titer of &lt;1:10 or (2) Four-fold increase in post-vaccination HI titer for subjects with pre-vaccination HI titer of ≥ 1:10
For each A strain, the comparion was made with the pooled TIV groups (Y+V minus QIV). For each B strain, the comparison was made with the corresponding TIV group(i.e. for B/Yamagata, Difference of SCR (Diff.SCR) is Y minus QIV).</description>
          <population>Per protocol set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="748"/>
                <count group_id="O2" value="371"/>
                <count group_id="O3" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.41" lower_limit="48.83" upper_limit="55.99"/>
                    <measurement group_id="O2" value="52.56" lower_limit="47.48" upper_limit="57.64"/>
                    <measurement group_id="O3" value="50.27" lower_limit="45.21" upper_limit="55.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.20" lower_limit="47.62" upper_limit="54.79"/>
                    <measurement group_id="O2" value="46.09" lower_limit="41.02" upper_limit="51.16"/>
                    <measurement group_id="O3" value="46.28" lower_limit="41.24" upper_limit="51.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.72" lower_limit="40.16" upper_limit="47.27"/>
                    <measurement group_id="O2" value="36.66" lower_limit="31.75" upper_limit="41.56"/>
                    <measurement group_id="O3" value="24.73" lower_limit="20.37" upper_limit="29.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.75" lower_limit="52.19" upper_limit="59.31"/>
                    <measurement group_id="O2" value="43.13" lower_limit="38.09" upper_limit="48.17"/>
                    <measurement group_id="O3" value="52.66" lower_limit="47.61" upper_limit="57.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Diff. SCR of A/H1N1 strain (SCR of pooled TIV minus QIV)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of SCR was concluded if the upper limit of 95% confidence interval for Diff. SCR (active comparator minus experimental) ≤10% for each strain.</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>-1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.07</ci_lower_limit>
            <ci_upper_limit>4.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Diff. SCR of A/H3N2 strain (SCR of pooled TIV minus QIV)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of SCR was concluded if the upper limit of 95% confidence interval for Diff. SCR (active comparator minus experimental) ≤10% for each strain.</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>-5.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.08</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Diff. SCR of B/Yamaga strain (SCR of TIV minus QIV)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of SCR was concluded if the upper limit of 95% confidence interval for Diff. SCR (active comparator minus experimental) ≤10% for each strain.</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>-7.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-13.12</ci_lower_limit>
            <ci_upper_limit>-1.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Diff. SCR of B/Victoria (SCR of TIV minus QIV)</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority of SCR was concluded if the upper limit of 95% confidence interval for Diff. SCR (active comparator minus experimental) ≤10% for each strain.</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>-3.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.26</ci_lower_limit>
            <ci_upper_limit>3.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection Rate (SPR) of NBP607-QIV in the Elderly Subject Aged ≥60 Years</title>
        <description>SPR of NBP607-QIV was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroprotection was defined as the proportion of subjects whose post-vaccination HI titer increased to ≥1:40.</description>
        <time_frame>At Day 21 post vaccination.</time_frame>
        <population>Per protocol set.</population>
        <group_list>
          <group group_id="O1">
            <title>NBP607-QIV</title>
            <description>Participants aged 60 years and older received a 0.5mL single intramuscular dose on Day 0
NBP607-QIV: Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rate (SPR) of NBP607-QIV in the Elderly Subject Aged ≥60 Years</title>
          <description>SPR of NBP607-QIV was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroprotection was defined as the proportion of subjects whose post-vaccination HI titer increased to ≥1:40.</description>
          <population>Per protocol set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.76" lower_limit="88.64" upper_limit="96.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.68" lower_limit="96.87" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.08" lower_limit="90.33" upper_limit="97.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.05" lower_limit="92.96" upper_limit="99.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion Rate (SCR) of NBP607-QIV in the Elderly Subject Aged ≥60 Years</title>
        <description>SCR was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroconversion was defined as the proportion of subjects who met either (1) post-vaccination HI titer of ≥ 1:40 for subjects with pre-vaccination HI titer of &lt;1:10 or (2) Four-fold increase in post-vaccination HI titer for subjects with pre-vaccination HI titer of ≥ 1:10</description>
        <time_frame>At Day 21 post vaccination.</time_frame>
        <population>Per protocol set.</population>
        <group_list>
          <group group_id="O1">
            <title>NBP607-QIV</title>
            <description>Participants aged 60 years and older received a 0.5mL single intramuscular dose on Day 0
NBP607-QIV: Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate (SCR) of NBP607-QIV in the Elderly Subject Aged ≥60 Years</title>
          <description>SCR was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroconversion was defined as the proportion of subjects who met either (1) post-vaccination HI titer of ≥ 1:40 for subjects with pre-vaccination HI titer of &lt;1:10 or (2) Four-fold increase in post-vaccination HI titer for subjects with pre-vaccination HI titer of ≥ 1:10</description>
          <population>Per protocol set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.63" lower_limit="44.69" upper_limit="60.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.11" lower_limit="34.26" upper_limit="49.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.42" lower_limit="35.54" upper_limit="51.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.87" lower_limit="52.08" upper_limit="67.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Ratio (GMR) of NBP607-QIV in the Elderly Subject Aged ≥60 Years</title>
        <description>GMR was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. GMR was defined as the fold-rise of the geometric mean HI titer from pre- to post-vaccination.</description>
        <time_frame>At Day 21 post vaccination.</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>NBP607-QIV</title>
            <description>Participants aged 60 years and older received a 0.5mL single intramuscular dose on Day 0
NBP607-QIV: Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio (GMR) of NBP607-QIV in the Elderly Subject Aged ≥60 Years</title>
          <description>GMR was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. GMR was defined as the fold-rise of the geometric mean HI titer from pre- to post-vaccination.</description>
          <population>Per protocol set</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.07" lower_limit="3.39" upper_limit="4.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27" lower_limit="2.69" upper_limit="3.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" lower_limit="2.59" upper_limit="3.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.61" lower_limit="3.91" upper_limit="5.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean HI Titers (GMTs) of Each B Strain After Vaccination in All Subjects</title>
        <description>GMTs of anti-influenza antibodies were measured for B strains: B/Victoria, and B/Yamagata.
For each B strain, the comparison was made with the TIV group which did not contain the correponding B strain (i.e. for B/Yamagata, Geometric Mean Titer Ratio (GMR) is V/QIV).</description>
        <time_frame>At Day 21 post vaccination.</time_frame>
        <population>Per protocol set.</population>
        <group_list>
          <group group_id="O1">
            <title>NBP607-QIV</title>
            <description>Participants aged 19 years and older received a 0.5mL single intramuscular dose on Day 0
NBP607-QIV: Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria</description>
          </group>
          <group group_id="O2">
            <title>NBP607-Y</title>
            <description>Participants aged 19 years and older received a 0.5mL single intramuscular dose on Day 0
NBP607-Y: Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata</description>
          </group>
          <group group_id="O3">
            <title>NBP607-V</title>
            <description>Participants aged 19 years and older received a 0.5mL single intramuscular dose on Day 0
NBP607-V: Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean HI Titers (GMTs) of Each B Strain After Vaccination in All Subjects</title>
          <description>GMTs of anti-influenza antibodies were measured for B strains: B/Victoria, and B/Yamagata.
For each B strain, the comparison was made with the TIV group which did not contain the correponding B strain (i.e. for B/Yamagata, Geometric Mean Titer Ratio (GMR) is V/QIV).</description>
          <population>Per protocol set.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="748"/>
                <count group_id="O2" value="371"/>
                <count group_id="O3" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163.74" lower_limit="156.11" upper_limit="171.73"/>
                    <measurement group_id="O2" value="144.65" lower_limit="135.54" upper_limit="154.37"/>
                    <measurement group_id="O3" value="123.08" lower_limit="115.39" upper_limit="131.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.82" lower_limit="119.16" upper_limit="130.75"/>
                    <measurement group_id="O2" value="93.29" lower_limit="87.43" upper_limit="99.53"/>
                    <measurement group_id="O3" value="112.20" lower_limit="105.20" upper_limit="119.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>GMR of B/Yamagata strain (GMTs of TIV/QIV)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of GMTs was concluded if the upper limit of 95% confidence interval for GMR (active comparator/experimental) was ≤1.0 for each B strain.</non_inferiority_desc>
            <param_type>GMR (TIV/QIV)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>GMR of B/Victoria (GMTs of TIV/QIV)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority of GMTs was concluded if the upper limit of 95% confidence interval for GMR (active comparator/experimental) was ≤1.0 for each B strain.</non_inferiority_desc>
            <param_type>GMR (TIV/QIV)</param_type>
            <param_value>0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.69</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Rate (SCR) of B Strain After Vaccination in All Subjects</title>
        <description>SCR was measured for each B strain: B/Victoria, and B/Yamagata. Seroconversion was defined as the proportion of subjects who met either (1) post-vaccination HI titer of ≥ 1:40 for subjects with pre-vaccination HI titer of &lt;1:10 or (2) Four-fold increase in post-vaccination HI titer for subjects with pre-vaccination HI titer of ≥ 1:10</description>
        <time_frame>At Day 21 post vaccination.</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>NBP607-QIV</title>
            <description>Participants aged 19 years and older received a 0.5mL single intramuscular dose on Day 0
NBP607-QIV: Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria</description>
          </group>
          <group group_id="O2">
            <title>NBP607-Y</title>
            <description>Participants aged 19 years and older received a 0.5mL single intramuscular dose on Day 0
NBP607-Y: Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata</description>
          </group>
          <group group_id="O3">
            <title>NBP607-V</title>
            <description>Participants aged 19 years and older received a 0.5mL single intramuscular dose on Day 0
NBP607-V: Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate (SCR) of B Strain After Vaccination in All Subjects</title>
          <description>SCR was measured for each B strain: B/Victoria, and B/Yamagata. Seroconversion was defined as the proportion of subjects who met either (1) post-vaccination HI titer of ≥ 1:40 for subjects with pre-vaccination HI titer of &lt;1:10 or (2) Four-fold increase in post-vaccination HI titer for subjects with pre-vaccination HI titer of ≥ 1:10</description>
          <population>Per protocol set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="748"/>
                <count group_id="O2" value="371"/>
                <count group_id="O3" value="376"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.72" lower_limit="40.16" upper_limit="47.27"/>
                    <measurement group_id="O2" value="36.66" lower_limit="31.75" upper_limit="41.56"/>
                    <measurement group_id="O3" value="24.73" lower_limit="20.37" upper_limit="29.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.75" lower_limit="52.19" upper_limit="59.31"/>
                    <measurement group_id="O2" value="43.13" lower_limit="38.09" upper_limit="48.17"/>
                    <measurement group_id="O3" value="52.66" lower_limit="47.61" upper_limit="57.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Diff. SCR of B/Yamaga strain (SCR of TIV minus QIV)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority was concluded if the upper limit of 95% confidence interval for Diff. SCR (active comparator-experimental) was ≤0% in each B strain.</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>-18.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.61</ci_lower_limit>
            <ci_upper_limit>-13.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Diff. SCR of B/Victoria strain (SCR of TIV minus QIV)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Superiority was concluded if the upper limit of 95% confidence interval for Diff. SCR (active comparator-experimental) was ≤0% in each B strain.</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>-12.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.79</ci_lower_limit>
            <ci_upper_limit>-6.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroprotection Rate (SPR) of NBP607-QIV in the Adults Aged 19 to 59 Years</title>
        <description>SPR of NBP607-QIV was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroprotection was defined as the proportion of subjects whose post-vaccination HI titer increased to ≥1:40.</description>
        <time_frame>At Day 21 post vaccination.</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>NBP607-QIV</title>
            <description>Participants aged 19 to 59 years received a 0.5mL single intramuscular dose on Day 0
NBP607-QIV: Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria</description>
          </group>
        </group_list>
        <measure>
          <title>Seroprotection Rate (SPR) of NBP607-QIV in the Adults Aged 19 to 59 Years</title>
          <description>SPR of NBP607-QIV was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroprotection was defined as the proportion of subjects whose post-vaccination HI titer increased to ≥1:40.</description>
          <population>Per protocol set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="596"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.32" lower_limit="97.29" upper_limit="99.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.50" lower_limit="98.93" upper_limit="100.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.49" lower_limit="97.51" upper_limit="99.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.16" lower_limit="98.43" upper_limit="99.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seroconversion Rate (SCR) of NBP607-QIV in the Adults Aged 19 to 59 Years</title>
        <description>SCR was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroconversion was defined as the proportion of subjects who met either (1) post-vaccination HI titer of ≥ 1:40 for subjects with pre-vaccination HI titer of &lt;1:10 or (2) Four-fold increase in post-vaccination HI titer for subjects with pre-vaccination HI titer of ≥ 1:10</description>
        <time_frame>At Day 21 post vaccination.</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>NBP607-QIV</title>
            <description>Participants aged 19 to 59 years received a 0.5mL single intramuscular dose on Day 0
NBP607-QIV: Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria</description>
          </group>
        </group_list>
        <measure>
          <title>Seroconversion Rate (SCR) of NBP607-QIV in the Adults Aged 19 to 59 Years</title>
          <description>SCR was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. Seroconversion was defined as the proportion of subjects who met either (1) post-vaccination HI titer of ≥ 1:40 for subjects with pre-vaccination HI titer of &lt;1:10 or (2) Four-fold increase in post-vaccination HI titer for subjects with pre-vaccination HI titer of ≥ 1:10</description>
          <population>Per protocol set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="596"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.35" lower_limit="48.34" upper_limit="56.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.52" lower_limit="49.52" upper_limit="57.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.79" lower_limit="39.81" upper_limit="47.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.70" lower_limit="50.70" upper_limit="58.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Ratio (GMR) of NBP607-QIV in the Subjects Aged 19 to 59 Years</title>
        <description>GMR was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. GMR was defined as the fold-rise of the geometric mean HI titer from pre- to post-vaccination</description>
        <time_frame>At Day 21 post vaccination.</time_frame>
        <population>Per protocol set</population>
        <group_list>
          <group group_id="O1">
            <title>NBP607-QIV</title>
            <description>Participants aged 19 to 59 years received a 0.5mL single intramuscular dose on Day 0
NBP607-QIV: Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Ratio (GMR) of NBP607-QIV in the Subjects Aged 19 to 59 Years</title>
          <description>GMR was measured for 4 strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata. GMR was defined as the fold-rise of the geometric mean HI titer from pre- to post-vaccination</description>
          <population>Per protocol set</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="596"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.83" lower_limit="4.29" upper_limit="5.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" lower_limit="3.45" upper_limit="4.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.21" lower_limit="2.95" upper_limit="3.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B/Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.08" lower_limit="3.73" upper_limit="4.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1) Incidence rate of solicited adverse events (AEs) occured within 7 days after test drug or comparator vaccination 2) Incidence rate of unsolicited AEs occured within 21 days after test drug or comparator vaccination 3) Incidence rate of serious adverse events (SAEs) occured within 6 months after test drug or comparator vaccination</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NBP607-QIV</title>
          <description>Participants aged 19 years and older received a 0.5mL single intramuscular dose on Day 0
NBP607-QIV: Quadrivalent Inactivated Cell Culture-derived Influenza Vaccine containing 4 virus strains; A/H1N1, A/H3N2, B/Yamagata, B/Victoria</description>
        </group>
        <group group_id="E2">
          <title>NBP607-Y</title>
          <description>Participants aged 19 years and older received a 0.5mL single intramuscular dose on Day 0
NBP607-Y: Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Yamagata</description>
        </group>
        <group group_id="E3">
          <title>NBP607-V</title>
          <description>Participants aged 19 years and older received a 0.5mL single intramuscular dose on Day 0
NBP607-V: Trivalent Inactivated Cell Culture-derived Influenza Vaccine containing 3 virus strains; A/H1N1, A/H3N2, B/Victoria</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="752"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="752"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>acute abdomen</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="752"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="752"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="752"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="752"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="752"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="752"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>otitis externa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="752"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="752"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="752"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="752"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>prostatic specific antigen increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="752"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign breast neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="752"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="752"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="752"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <description>Mild Severity, recovered, unrelated to NBP607-QIV</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="752"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>colon operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="752"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="373"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="364" subjects_at_risk="752"/>
                <counts group_id="E2" subjects_affected="154" subjects_at_risk="373"/>
                <counts group_id="E3" subjects_affected="151" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="752"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="373"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="752"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" events="207" subjects_affected="207" subjects_at_risk="752"/>
                <counts group_id="E2" events="84" subjects_affected="84" subjects_at_risk="373"/>
                <counts group_id="E3" events="81" subjects_affected="81" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="198" subjects_affected="198" subjects_at_risk="752"/>
                <counts group_id="E2" events="70" subjects_affected="70" subjects_at_risk="373"/>
                <counts group_id="E3" events="71" subjects_affected="71" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Induration/swelling</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="752"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="373"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Fatigue/Malaise</sub_title>
                <counts group_id="E1" events="101" subjects_affected="101" subjects_at_risk="752"/>
                <counts group_id="E2" events="71" subjects_affected="71" subjects_at_risk="373"/>
                <counts group_id="E3" events="60" subjects_affected="60" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="752"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="373"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="130" subjects_affected="130" subjects_at_risk="752"/>
                <counts group_id="E2" events="58" subjects_affected="58" subjects_at_risk="373"/>
                <counts group_id="E3" events="55" subjects_affected="55" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="71" subjects_affected="71" subjects_at_risk="752"/>
                <counts group_id="E2" events="35" subjects_affected="35" subjects_at_risk="373"/>
                <counts group_id="E3" events="38" subjects_affected="38" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Redness/erythema</sub_title>
                <counts group_id="E1" events="44" subjects_affected="44" subjects_at_risk="752"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="373"/>
                <counts group_id="E3" events="14" subjects_affected="14" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hayoung Lee</name_or_title>
      <organization>SK bioscience</organization>
      <phone>+82-2-2008-2552</phone>
      <email>haylee@sk.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

